A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Tuesday, August 13, 2013
The Myelin Repair Foundation Partners with Gencia Corporation to Advance Myelin Repair Therapeutics for Multiple Sclerosis (MS)
TheMyelin Repair Foundation (MRF) and Gencia Corporation today announced a collaboration to advance myelin repair therapeutic development for Multiple Sclerosis (MS). Through its unique Accelerated Research Collaboration™ (ARC™) model, the Myelin Repair Foundation will partner with Gencia Corporation to assess the myelin regenerating capabilities of the company’s proprietary therapeutic compounds for MS.
Through this unique partnership, Gencia Corporation will work closely with researchers at the Myelin Repair Foundation’s Translational Medicine Center, a laboratory facility dedicated to the evaluation of promising multiple sclerosis candidates for myelin repair. Led by MRF personnel with extensive biopharma experience moving therapeutic compounds into the clinic, the MRF Translational Medicine Center investigates and advances promising myelin repair drug targets toward commercialization.
“The Myelin Repair Foundation’s patient-centric, collaborative approach to develop the next generation of MS therapeutics makes them an ideal partner for us to bring new treatments to the clinic,” said President and CEO Allen Cunningham from Gencia Corporation. “We are excited to work side by side with MRF, utilizing their novel myelin repair research tools and assays at the MRF Translational Medicine Center. With this partnership, we are well positioned to expedite myelin repair therapeutics development forward, meeting the needs of MS patients.”
“Gencia’s forward-thinking approach to remyelination aligns nicely with our goal to bring the next generation of MS treatments to patients,” said Chief Research Officer Dr. Jay Tung, Ph.D, from the Myelin Repair Foundation. “We are thrilled to be working with Gencia to examine new ways to treat MS. As a non-profit organization, we seek to partner with innovative companies doing exciting MS research in myelin repair.”
The Myelin Repair Foundation’s rigorous, industry-leading Translational Medicine Platformconsists of its Translational Medicine Center, contract research organizations and the MRF’s research consortium. The goal of the MRF Translational Medicine Platform is to ensure comprehensive validation of potential therapeutics into clinical development.